Tarceva PFS data much better than chemo in NSCLC
This article was originally published in Scrip
Executive Summary
Roche’s EGFR targeted drug Tarceva (erlotinib) nearly tripled progression-free survival (PFS) compared with standard chemotherapy in its first prospective Phase III trial in newly diagnosed, advanced non-small cell lung cancer (NSCLC) patients whose tumours carry EGFR activating mutations. The results were presented at the ESMO meeting in Milan, Italy.